Chimerix Inc. (CMRX)
NASDAQ (NMS) 
Summary
CMRX Chart
Jazz Pharmaceuticals Completes Acquisition of Chimerix
- Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need - DUBLIN , April 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc. ("Chimerix") for approximately $935 million in cash. Chimerix is now a wholly owned subsidiary of Jazz.
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., March 07, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on March 2, 2025, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 70,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4).
Chimerix Inc. (CMRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Chimerix Inc. ever had a stock split?
Chimerix Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Michael T. Andriole M.B.A. CEO | NASDAQ (NMS) Exchange | 16934W106 Cusip |
| United States Country | 72 Employees | - Last Dividend | - Last Split | 11 Apr 2013 IPO Date |
Overview
Chimerix, Inc. is a pioneering biopharmaceutical company with a sole focus on inventing and refining treatments aimed at enhancing and prolonging the lives of patients grappling with lethal diseases. Since its establishment in 2000, Chimerix has dedicated itself to pushing the boundaries of medical science, using cutting-edge research and development strategies to tackle some of the most challenging health conditions. The company’s operational and research headquarters are strategically located in Durham, North Carolina, positioning it at the heart of one of the country’s leading biotech hubs.
Products and Services
The innovative pipeline of Chimerix, Inc. includes a range of groundbreaking products in various stages of clinical trials, targeting a spectrum of deadly diseases:
- ONC201: This exceptional program is currently undergoing a Phase 3 clinical trial as a promising treatment option for patients with H3 K27M-mutant diffuse glioma, a rare and aggressive type of brain tumor. Additionally, ONC201 is in a Phase 2 trial aimed at combating rare neuroendocrine tumors. The hope vested in ONC201 stems from its potential to provide critical solutions to patients with few to no therapeutic options.
- ONC206: Identified as an imipridone, ONC206 combines the mechanism of being a Dopamine Receptor D2 (DRD2) antagonist and a caseinolytic protease P (ClpP) agonist. It is presently in Phase 1 clinical trials, focusing on adult and pediatric patients battling primary central nervous system tumors. ONC206 represents Chimerix's commitment to advancing cancer therapy through novel and multifaceted modalities.
- ONC212: As another member of the imipridone family, ONC212 uniquely functions as an agonist for the orphan G protein-coupled receptor (GPCR) tumor suppressor GPR132 and ClpP. The drug is targeted towards various oncology indications, embodying the company’s broader strategy to leverage GPCR-targeted therapies in cancer treatment.
- CMX521: Diverging from oncology, CMX521 signifies Chimerix's foray into antiviral therapy, specifically designed as a nucleoside analog to combat SARS-CoV-2, the virus responsible for COVID-19. This development reflects the company's adaptability and responsiveness to global health crises by expanding its research focus beyond cancer.
In its strategic endeavors, Chimerix has entered into a licensing agreement with SymBio Pharmaceuticals. This collaboration is geared towards the development and commercialization of TEMBEXA, excluding its use against orthopoxviruses, like smallpox, thus exemplifying Chimerix’s versatile approach to addressing a broad range of human diseases.
Contact Information
